Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash & Equivalents: 2014-2024

Historic Cash & Equivalents for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to $89.4 million.

  • Spyre Therapeutics' Cash & Equivalents fell 9.34% to $64.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.9 million, marking a year-over-year decrease of 9.34%. This contributed to the annual value of $89.4 million for FY2024, which is 52.66% down from last year.
  • As of FY2024, Spyre Therapeutics' Cash & Equivalents stood at $89.4 million, which was down 52.66% from $188.9 million recorded in FY2023.
  • Spyre Therapeutics' 5-year Cash & Equivalents high stood at $188.9 million for FY2023, and its period low was $15.1 million during FY2021.
  • For the 3-year period, Spyre Therapeutics' Cash & Equivalents averaged around $104.4 million, with its median value being $89.4 million (2024).
  • In the last 5 years, Spyre Therapeutics' Cash & Equivalents tumbled by 83.19% in 2021 and then soared by 441.82% in 2023.
  • Over the past 5 years, Spyre Therapeutics' Cash & Equivalents (Yearly) stood at $90.1 million in 2020, then crashed by 83.19% to $15.1 million in 2021, then surged by 130.24% to $34.9 million in 2022, then soared by 441.82% to $188.9 million in 2023, then slumped by 52.66% to $89.4 million in 2024.